

A SPECIALTY LIFE SCIENCES COMPANY

Corporate Presentation
November 2020



US:
RVVTF

Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: mfrank@revivetherapeutics.com

FORWARD LOOKING STATEMENTS



Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward-looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes and plans and objectives. In some cases, forward-looking information can be identified by terms such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts. These statements are based on certain factors and assumptions regarding, among other things, expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable based on information currently available to us, they may prove to be incorrect. Forward looking-information is also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors include, among other things, the availability of funds and resources to pursue development projects, the successful and timely completion of clinical studies, and the ability to take advantage of business opportunities, the granting of necessary approvals by regulatory authorities, and general economic, market and business conditions. For more exhaustive information on these risks and uncertainties you should refer to our most recently filed Annual Information Form which is available at www.sedar.com. Forward-looking information contained in this presentation is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.

REVIVE THERAPEUTICS



Specialty life sciences company focused on repurposing drugs for rare disorders and infectious diseases



FDA approved Phase 3 clinical trial for Bucillamine in the treatment of COVID-19



Developing novel Psilocybin and Cannabidiol therapeutics for various CNS and inflammatory disorders




Robust patent portfolio covering methods and compositions of drugs




Near-term value creation milestones


Bucillamine



Psilocybin



Cannabidiol



PHARMACEUTICAL STRATEGY



Clinical development of
Psilocybin, Cannabidiol
and Bucillamine



Targeting Rare
Disorders and
Infectious Diseases



Novel Uses,
Formulations, and
Delivery System



Targeting FDA
Designations:
Orphan, Fast track,
Breakthrough
therapy



PATENT PORTFOLIO



Title	USPTO No.	Status
Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19	62/991,996	Provisional patent filed
Use of Bucillamine in the Treatment of Gout	US9662305	Issued on May 30, 2017
Drug Delivery System	US 8642088 US 9545423 US 10104888	Issued on February 4, 2014 Issued on January 17, 2017 Issued on October 23, 2018
Psilocybin effervescent and psilocybin tablet - Solid Oral Pharmaceutical Compositions	62/985,052	Provisional patent filed
Psilocybin hard-shell capsules - Pharmaceutical Capsule Compositions	62/985,070	Provisional patent filed
Psilocybin gum drops - Pharmaceutical Gumdrops Compositions	62/985,084	Provisional patent filed
Psilocybin oral strips and transmucosal - Thin-Film Pharmaceutical Delivery System and Formulations	62/985,098	Provisional patent filed
Psilocybin - Pharmaceutical Formulations and Methods for Sublingual and Buccal Administration	62/984,590	Provisional patent filed
Methods for the Extraction and Crystallization of Psilocybin	62/985,360	Provisional patent filed
Use of Cannabidiol in the Treatment of Autoimmune Hepatitis	US 8242178	Issued on August 14, 2012

PRODUCT PIPELINE



Focus on Infectious Diseases, Psychedelics and Rare Disorders

Product	Indication	Stage of Development	Regulatory Status
Bucillamine	Infectious Diseases (COVID-19)	Phase 3 (COVID-19)	FDA approved for Phase 3
Psilocybin	Methamphetamine Use Disorder	Phase 1	CTA with University of Wisconsin
Psilocybin (Oral Formulations)	Depression, Anxiety, etc.	Pre-clinical	Target FDA Approval
CBD	Liver Diseases (Autoimmune Hepatitis)	Filing IND	Plan for Phase 2

INFECTIOUS DISEASE OPPORTUNITY



Received FDA approval for
[FDA Phase 3](#) clinical trial
for COVID-19



Focus on Bucillamine in
the treatment of
infectious diseases

- Well-known safety profile and prescribed for arthritis in Japan and South Korea for over 30 years



Revive's clinical history
with Bucillamine

- Obtained 2 FDA INDs with Bucillamine and FDA orphan drug status
- FDA Phase 2 clinical study for acute gout flares and cystinuria



Bucillamine (BUC) scientific
rationale as an intervention for
COVID-19 (see Appendix)

- BUC is 16x more potent than particularly N-acetylcysteine (NAC); NAC has shown to prevent acute lung injury caused by influenza virus
- BUC shown superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection
- BUC also shown to prevent oxidative and reperfusion injury in heart and liver tissues
- BUC proven safety and MOA similar to NAC, but with much higher potency

PSYCHEDELICS OPPORTUNITY



Acquired Psilocin Pharma Corp.

- Derrick Welch, Founder with 14 years of HC experience; 5 years in Cannabis
- Worked with Xanthic Bio Pharma and Green Growth Brands
- Developed water Soluble THC and CBD products (Beverages, effervescent tablets)



Novel Psilocybin formulations, extraction and purification methods

- Suited for pharmaceutical development and recreational markets where legal




Patent pending Psilocybin formulations (natural and synthetic derived)

- Capsules, Sublingual Spray, Gel Cap, Effervescent Tablets, and Oral Strips



Targeting mental health, addiction and rare diseases



Psilocin Pharma Corp.

A Subsidiary of Revive Therapeutics Ltd.

FORMULATION & DELIVERY TECHNOLOGY

Delivering naturally extracted and synthetic psychedelics and cannabinoids



DELIVERY SYSTEM

Combines **Tannin** (antibacterial, antifungal, antioxidant, wound healing) and **Chitosan** (blood-clotting and antimicrobial) composites

- ✓ Releases (rapid, controlled, sustained), improved bioavailability, no first-pass metabolism




PSILOCYBIN

Precise dosed formulations i.e. capsules, sublingual spray, gel caps, effervescent tablets and oral/transmucosal strips



CANNABIDIOL

Novel combination of composites allowing for multiple delivery formats, potential synergistic and therapeutic effects



LIVER DISEASE OPPORTUNITY

Focus on Autoimmune Hepatitis (AIH)



AIH - rare disease (~76k patients in US) causing liver inflammation

Drawbacks of current therapies (steroids):
Severe side effects in 13%, relapse after drug withdrawal in 50%-86%*

- ✓ Obtained FDA orphan drug status for CBD in the treatment of AIH
- ✓ Seeking to file FDA IND to conduct Phase 2 clinical study in patients affected by AIH

Big Pharma interest in liver diseases




Allergan acquisition of Tobira for
\$1.7 billion



Novartis license of Conatus drug for
\$650 million



Gilead acquisition of Nimbus for
\$1.2 billion



STRATEGIC PARTNERS



Infectious Diseases CRO



Acquired March 2020
Psychedelic pharma



R&D partnership
Psychedelic pharma



License of cannabidiol for treatment
of Autoimmune Hepatitis



License of cannabinoid
delivery technology

MILESTONES

Q4
2020

- Patient enrollment of Phase 3 study of Bucillamine in the treatment of COVID-19
- Ongoing updates from Phase 3 clinical study of Bucillamine in the treatment of COVID-19
- Submit IND for Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis


Q1
2021

- Continued patient enrollment and ongoing updates from Phase 3 clinical study of Bucillamine in the treatment of COVID-19
- Pre-IND meeting with FDA for Bucillamine in various infectious diseases (undisclosed)
- Pre-IND meeting with FDA for Psilocybin (oral formulations – mental health disorders)
- Submit IND with FDA for Psilocybin (oral formulations – mental health disorders)
- Initiate Phase 1 study for Methamphetamine Use Disorder
- Initiate Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis


Q2
2021

- Continued patient enrollment and ongoing updates from Phase 3 clinical study of Bucillamine in the treatment of COVID-19
- Complete Phase 3 study of Bucillamine in the treatment of COVID-19
- Submit IND with FDA for Bucillamine for other infectious disease indications

PEER COMPARISON (MARKET CAPS)



TEAM



Management

- **Michael Frank**
Chairman and CEO
- **Carmelo Marrelli**
Chief Financial Officer
- **Derrick Welsh**
Founder, Psilocin Pharma Corp.



Clinical & Regulatory

- **Dr. Kelly McKee, Jr., MD, MPH**
Chief Scientific Officer,
Consultant
- **Dr. Onesmo Mpanju, PhD**
FDA Regulatory Affairs,
Consultant



Board of Directors

- **Michael Frank**
Chairman and CEO
- **William Jackson**
Director
- **Joshua Herman**
Director
- **Christian Scovenna**
Director
- **Andrew Lindzon**
Director

STOCK INFORMATION



Ticker

RVV (CSE) | RVVTF (US)



52-Week High/Low

CAD \$0.395 / \$0.025



Market Cap

CAD ~ \$50,000,000



Share Price

CAD \$0.215 (November 18, 2020)



Capital Structure

240,526,239 common shares

APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19



Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.^{1,2} Novel antivirals have been plagued by poor oral bioavailability and lack of efficacy when not delivered early.¹ This is because these drugs mostly act to prevent the early processes of virus binding to cells or viral replication.² Thiols, particularly N-acetylcysteine (NAC), with antioxidant and reducing activity have been investigated as effective therapies that abrogate the potential for influenza to cause severe disease.^{3,4,5} Restoration of glutathione, the major intracellular thiol antioxidant, is a critical functional activity of NAC.⁶ Reactive oxygen species (ROS) generation during influenza virus infection aggravate destructive inflammation and programmed death of epithelial cells.⁷ Studies in human cells and animal models have shown that NAC works to prevent acute lung injury caused by influenza virus infection through inhibition of these ROS-mediated mechanisms.^{4,7} NAC has been investigated clinically and found to significantly attenuate clinical symptoms associated with influenza infection, especially in elderly at-risk patients.⁵ While NAC is easily taken up by cells and has low toxicity, clinical efficacy has required long-term and high-dose administration because of modest relative potency, limiting its clinical applicability.

Bucillamine (N-(mercapto-2-methylpropionyl)-L-cysteine), which has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years, is a cysteine derivative with 2 thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection.⁸ Bucillamine has also been shown to prevent oxidative and reperfusion injury in heart and liver tissues⁸ and is highly cell permeable for efficient delivery into cells.^{8,9} Bucillamine has unrealized potential for the treatment of influenza with both proven safety and proven mechanism of action similar to that of NAC, but with much higher potency, mitigating the previous obstacles to using thiols therapeutically. It is also reasonable to hypothesize that similar processes related to ROS are involved in acute lung injury during nCov-19 infection, possibly justifying the investigation of Bucillamine as an intervention for COVID-19.

APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19



References

1. [Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data Lancet Respir Med. 2014 May;2\(5\):395-404. doi: 10.1016/S2213-2600\(14\)70041-4.](#)
2. [Duwe S. Influenza viruses – antiviral therapy and resistance. GMS Infect Dis. 2017; 5: Doc04.](#)
3. [Zhang RH, Li CH, Wang CL et al. N-acetyl-L-cystine \(NAC\) protects against H9N2 swine influenza virus-induced acute lung injury. Int Immunopharmacol. 2014 Sep;22\(1\):1-8. doi: 10.1016/j.intimp.2014.06.013.](#)
4. [Ungheri D, Pisani C, Sanson G et al. Protective effect of n-acetylcysteine in a model of influenza infection in mice. Int J Immunopathol Pharmacol. 2000 Sep-Dec;13\(3\):123-128.](#)
5. [De Flora S, Grassi C, and Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997; 10: 1535–1541 DOI: 10.1183/09031936.97.10071535](#)
6. [Poole LB. The Basics of Thiols and Cysteines in Redox Biology and Chemistry. Free Radic Biol Med. 2015 Mar; 0: 148–157. doi: 10.1016/j.freeradbiomed.2014.11.013.](#)
7. [Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-L-cysteine \(NAC\) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus \(RSV\). Biochem Pharmacol. 2011 Sep 1;82\(5\):548-55. doi: 10.1016/j.bcp.2011.05.014.](#)
8. [Horowitz LD. Bucillamine: a potent thiol donor with multiple clinical applications. Cardiovasc Drug Rev. 2003 Summer;21\(2\):77-90.](#)
9. [Sagawa A, Fujisaku A, Ohnishi K et al. A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis \(SNOW study\). Mod Rheumatol. 2011 Jun;21\(3\):251-7. doi: 10.1007/s10165-010-0385-4](#)